Email this article 
Post a Comment Clinical significance of immunoprophylaxis of respiratory syncytial viral infection in premature children at early age
- Authors: Ibrahimova Y.N.1,2, Vakhlova I.V.1, Vlasova E.V.2, Krivolapova I.M.1,2
-
Affiliations:
- Ural State Medical University
- Regional Children's Clinical Hospital
- Issue: Vol 42, No 2 (2025)
- Pages: 94-103
- Section: Preventive and social medicine
- URL: https://bakhtiniada.ru/PMJ/article/view/294282
- DOI: https://doi.org/10.17816/pmj42294-103
- ID: 294282
Cite item
Full Text
Abstract
Objective. To estimate the clinical significance of immunoprophylaxis of RSV infection in premature infants of high-risk groups at an early age.
Materials and methods. A prospective cohort study was conducted in young children depending on the presence of RSVI immunoprophylaxis (total n = 216). 2 main and 1 control group were formed: group 1 (n = 104) consisted of children who underwent courses of RSVI immunoprophylaxis (immunization "+"), group 2 (n = 97) included children without immunization (immunization "-"), control group (healthy children, n = 15). Clinical and anamnestic methods included: perinatal history, incidence of acute respiratory diseases (ARD), incidence of cases of bronchial obstruction; laboratory methods were used to identify biomarkers of lung tissue remodeling (total n = 77, group 1/n = 44 and group 2/n = 33): matrix metalloproteinases-2 and 9 (MMP-2, MMP-9), tissue inhibitor of matrix metalloproteinase-2 (TIMMP-2); vascular endothelial growth factor (VEGF) (total n = 92, group 1/n = 44, group 2/n = 33, control/n = 15); echocardiography (Echo-CG) was used as an instrumental non-invasive method to exclude the diagnosis of pulmonary hypertension.
Results. RSV immunoprophylaxis in the 1st year of life has demonstrated a decrease in the incidence of acute respiratory diseases (p < 0.024) and a reduced risk for bronchial obstruction (p < 0.033) and pneumonia (p < 0.079) at the age of 1–3 years. The lack of RSVI immunoprophylaxis contributes significantly to the development of cases of bronchial obstruction (AP = 46 %) in the early age period. The association between the levels of biomarkers of pulmonary tissue remodeling in the blood serum with the frequency of episodes of bronchial obstruction at the age of 1–3 has been proved.
Conclusions. The use of monoclonal antibodies in children at risk for developing RSV bronchiolitis reduces the incidence of ARD, episodes of bronchial obstruction in the early age period. There was a direct association between the incidence of bronchial obstruction and levels of MMR-9, TIMMP-2 and VEGF-D in the blood serum of children aged 1–3 years depending on immunoprophylaxis.
Full Text
##article.viewOnOriginalSite##About the authors
Yu. N. Ibrahimova
Ural State Medical University; Regional Children's Clinical Hospital
Author for correspondence.
Email: Julia080685@gmail.com
ORCID iD: 0000-0003-4053-4405
Assistant of the Department of Hospital Pediatrics, Pediatrician
Russian Federation, Yekaterinburg; YekaterinburgI. V. Vakhlova
Ural State Medical University
Email: Julia080685@gmail.com
ORCID iD: 0000-0002-5274-4699
DSc (Medicine), Professor, Head of the Department of Hospital Pediatrics
Russian Federation, YekaterinburgE. V. Vlasova
Regional Children's Clinical Hospital
Email: Julia080685@gmail.com
ORCID iD: 0000-0002-6678-5360
PhD (Medicine), Head of the Department of Clinical Immunology, Allergist-Immunologist
Russian Federation, YekaterinburgI. M. Krivolapova
Ural State Medical University; Regional Children's Clinical Hospital
Email: Julia080685@gmail.com
ORCID iD: 0000-0001-7922-3810
PhD (Biology), Senior Laboratory Assistant of the Department of Hospital Pediatrics, Biologist of the Department of Immunology of CLD
Russian Federation, Yekaterinburg; YekaterinburgReferences
- Кршеминская И.В., Овсянников Д.Ю., Дегтярев Д.Н., Дегтярева Е.А. Респираторно-синцитиальный вирусный бронхиолит у недоношенных детей и предикторы его тяжелого течения. Неонатология: новости, мнения, обучение 2016; 2 (12): 67–80. / Krsheminskaya I.V., Ovsyannikov D.Yu., Degtyarev D.N., Degtyareva E.A. Respiratory syncytial viral bronchiolitis in nedonoshennykh children and predictors of its severe course. Neonatology: news, opinions, training 2016; 2 (12): 67–80 (in Russian).
- Игнатьева В.И., Овсянников Д.Ю., Цыганков А.Е., Ягненкова Е.Е., Амирова В.Р., Маранян М.М., Мокрова А.С. Социально-экономическое бремя респираторно-синцитиальной вирусной инфекции нижних дыхательных путей у детей в возрасте от рождения до 5 лет в Российской Федерации: результаты моделирования. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология 2023; 16 (4): 517–525. / Ignatieva V.I., Ovsyannikov D.Yu., Tsygankov A.E., Yagnenkova E.E., Amirova V.R., Maranyan M.M., Mokrova A.S. Socio-economic burden of respiratory syncytial viral infection of the lower respiratory tract in children aged from birth to 5 years in the Russian Federation: simulation results. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology 2023; 16 (4): 517–525. doi: 10.17749/2070-4909/farmakoekonomika.2023.217
- Konstantinos Karampatsas, Jonathan Kong. Bronchiolitis: an update on management and prophylaxis. British Journal of Hospital Medicine 2019; 5: 278–284. doi: 10.12968/hmed.2019.80.5.278
- Tavares V.B., E Souza J.S., Affonso M.V.G. et al. Factors associated with 5-min APGAR score, death and survival in neonatal intensive care: a case-control study. BMC Pediatr 2022; 22 (1): 560. doi: 10.1186/s12887-022-03592-9
- Wang X.-Y., Wang B., Wen Y.-M. From therapeutic antibodies to immune complex vaccines. npj Vaccines. 2019; 4 (1): 2. doi: 10.1038/s41541-018-0095-z
- Баранов А.А., Намазова-Баранова Л.С. и др. Иммунопрофилактика респираторно-синцитиальной вирусной инфекции у детей. Педиатрическая фармакология 2015; 12 (5): 543–549. doi: 10.15690/pf.v12i5.1456 / Baranov A.A., Namazova-Baranova L.S. et al. Immunoprophylaxis of respiratory syncytial viral infection in children. Pediatric Pharmacology 2015; 12 (5): 543–549. doi: 10.15690/pf.v12i5.1456 (in Russian).
- Межинский С.С., Мостовой А.В., Карпова А.Л., Горев В.В., Овсянников Д.Ю., Заплатников А.Л. Стратегии респираторной терапии с тяжелой бронхолегочной дисплазией. Педиатрия им. Г.Н. Сперанского 2024; 103: 146–152. / Mezhinsky S.S., Mostovoy A.V., Karpova A.L., Gorev V.V., Ovsyannikov D. Yu., Patnikov A.L. Respiratory therapy strategies with severe bronchopulmonary dysplasia. Pediatriya n.a. G.N. Speranskoy 2024; 103: 146–152 (in Russian).
- Yeoh D.K., Foley D.A., Minney-Smith C.A., Martin A.C., Mace A.O., Sikazwe C.T., et al. Impact of Coronavirus Disease 2019 Public Health Measures on Detections of Influenza and Respiratory Syncytial Virus in Children During the 2020 Australian Winter. Clin Infect Dis. 2021: 72 (12): 2199–2202. doi: 10.1093/cid/ciaa1475
- Adel S. Alharbi, Mohamed Alzahrani. Saudi experts’ recommendation for RSV prophylaxis in the еra of COVID-19. Clinical Practice Guidelines, February 2021. Saudi Med J 2021; 42 (4): 355–362. doi: 10.15537/smj.2021.42.4.20200769
- Simões E.A.F. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018; 7 (1): 87–120. doi: 10.1007/s40121-018-0188-z
- Rosenberg G.A. Matrix metalloproteinases and extracellular matrix in the central nervous system. Primer on Cerebrovascular Diseases. 2017; 291–295. doi: 10.1016/b978-0-12-803058-5.00061-8
- Checchia P.A., NaLysnyk L., Fernandes A.W. et al. Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: systematic literature review and meta-analysis. Pediatr. Crit Care Med. J. 2011; 12 (5): 580–588. doi: 10.1097/PCC.0b013e3182070990
- Tissot C., Singh Y., Younoszai A.K., Phelps C.M. Echocardiography. Critical Care of Children with Heart Disease. Eds. R. Munoz, V. Morell, E. da Cruz, C. Vetterly, J. da Silva. Springer, Cham 2020. doi: 10.1007/978-3-030-21870-6_6
- Кршеминская И.В., Кравчук Д.А., Овсянников Д.Ю., Болибок А.М., Павлова Е.С., Ларина В.Н. Влияние иммунопрофилактики респираторно-синцитиальной вирусной инфекции паливизумабом на развитие бронхиальной астмы у детей с бронхолегочной дисплазией. Педиатрия им. Г.Н. Сперанского 2020; 99 (2): 63–68. / Krsheminskaya I.V., Kravchuk D.A., Ovsyannikov D.Yu., Bolibok A.M., Pavlova E.S., Larina V.N. Effect of immunoprophylaxis of respiratory syncytial viral infection with palivizumab on the development of bronchial asthma in children with bronchopulmonary dysplasia. Pediatria n.a. G.N. Speransky 2020; 99 (2): 63–68 (in Russian).
- Кельмансон И.А. Принципы доказательной педиатрии. Санкт-Петербург: Фолиант, 2004; 240. / Kelmanson I.A. Principles of evidence-based pediatrics. Sankt-Peterburg: Foliant 2004; 240 (in Russian).
- Ибрагимова Ю.Н., Вахлова И.В., Криволапова И.М. Влияние пассивной иммунопрофилактики респираторно-синцитиальной вирусной инфекции на частоту и тяжесть течения острых респираторных заболеваний и уровень протеолитических ферментов у детей 1–3 лет. Российский вестник перинатологии и педиатрии 2024; 69 (6): 66–72. doi: 10.21508/1027–4065–2024–69–6–66–72 / Ibragimova Yu.N., Vakhlova I.V., Krivolapova I.M. The effect of passive immunoprophylaxis of respiratory syncytial virus infection on the frequency and severity of acute respiratory diseases and the level of proteolytic enzymes in children 1–3 years. Russian Bulletin of Perinatology and Pediatrics 2024; 69: (6): 66–72. doi: 10.21508/1027–4065–2024–69–6–66–72 (in Russian).
Supplementary files
